Scientific independence and objectivity: many questions linger about treatment of type 2 diabetes, such as scientific study design, optimal glucose control and the safety of injecting exogenous insulin

References

• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149.
   PubMed Web of Science ®Google Scholar
• National Institute for Care and Clinical Excellence. Type 2 diabetes in adults: management. [cited 2017 Mar 28]. Available from: https://www.nice.org.uk/guidance/ng28/chapter/1-recommendations#individualised-care
   Google Scholar
• Holden SE, Jenkins-Jones S, Morgan CL, et al. Prevalence, glucose control and relative survival of people with Type 2 diabetes in the UK from 1991 to 2013. Diabet Med. 2017. DOI:10.1111/dme.13332
   PubMed Web of Science ®Google Scholar
• Holden SE, Gale EA, Jenkins-Jones S, et al. How many people inject insulin? UK estimates from 1991 to 2010. Diabetes Obes Metab. 2014;16:553–559.
   PubMed Web of Science ®Google Scholar
• Gale EA. Glucose control in the UKPDS: what did we learn? Diabet Med. 2008;25(Suppl 2):9–12.
   PubMedGoogle Scholar
• Bannister CA, Holden SE, Jenkins-Jones S, et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab. 2014;16:1165–1173.
   PubMed Web of Science ®Google Scholar
• Drazen JM, Morrissey S, Curfman GD. Rosiglitazone–continued uncertainty about safety. N Engl J Med. 2007;357:63–64.
   PubMed Web of Science ®Google Scholar
• Bain S, Druyts E, Balijepalli C, et al. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes Obes Metab. 2017;19:329–335.
   PubMed Web of Science ®Google Scholar
• Morgan CL, Mukherjee J, Jenkins-Jones S, et al. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. Diabetes Obes Metab. 2014;16:957–962.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Gale EA, Poole CD. Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007. Diabet Med. 2010;27(8):938–948.
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care. 2017;40(4):468–475.
   PubMed Web of Science ®Google Scholar
• Tsujimoto T, Kajio H, Sugiyama T. Favourable changes in mortality in people with diabetes: US NHANES 1999–2010. Diabetes Obes Metab. 2017. [Epub ahead of print]. DOI:10.1111/dom.13039
   Web of Science ®Google Scholar
• Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370(16):1514–1523.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al., PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289..
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al., EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128..
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al., CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657..
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al., LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2016;375(4):311–322..
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al., SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Atar D. Viewpoint: central adjudication of myocardial infarction in outcome-driven clinical trials–common patterns in TRITON, RECORD, and PLATO? Thromb Haemost. 2012;108:412–414.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (Prospective pioglitazone clinical trial in microvascular events): a randomised controlled trial. Lancet. 2005;366:1279–1289.
   PubMed Web of Science ®Google Scholar
• Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer. Lancet. 2011;378: 1543–1544. author reply 4–5.
   PubMed Web of Science ®Google Scholar
• Erdmanna E, Dormandy JA, Massi-Benedetti M, et al. Pioglitazone and bladder cancer – authors’ reply. Lancet. 2011;378:1544–1545.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), Center for Devices and Radiological Health (CDRH). Guidance for clinical trial sponsors establishment and operation of clinical trial data monitoring committees. 2006. [cited 2015 Jan 30]. Available from: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Guideline on data monitoring committees. 2005. [cited 2015 Jan 30]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003635.pdf.
   Google Scholar
• Hróbjartsson A, Thomsen AS, Emanuelsson F, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. Br Med J. 2012;344:e1119.
   PubMed Web of Science ®Google Scholar
• Dechartres A, Trinquart L, Boutron I, et al. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. Br Med J. 2013;346:f2304.
   PubMed Web of Science ®Google Scholar
• Stuck AK, Fuhrer E, Limacher A, et al. Adjudication-related processes are underreported and lack standardization in clinical trials of venous thromboembolism: a systematic review. J Clin Epidemiol. 2014;67:278–284.
   PubMed Web of Science ®Google Scholar
• Investigators SPRINT, Simunovic N, Walter S, et al. Outcomes assessment in the SPRINT multicenter tibial fracture trial: adjudication committee size has trivial effect on trial results. J Clin Epidemiol. 2011;64:1023–1033.
   PubMed Web of Science ®Google Scholar
• Walter SD, Cook DJ, Guyatt GH, et al. Outcome assessment for clinical trials: how many adjudicators do we need? Canadian Lung Oncology Group. Control Clin Trials. 1997;18:27–42.
   PubMedGoogle Scholar
• Heddle NM, Wu C, Vassallo R, et al. Adjudicating bleeding events in a platelet dose study: impact on outcome results and challenges. Transfusion. 2011;51:2304–2310.
   PubMed Web of Science ®Google Scholar
• Hata J, Arima H, Zoungas S, et al., ADVANCE Collaborative Group. Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial. PLoS One. 2013;8:e55807.
   PubMedGoogle Scholar
• Ninomiya T, Donnan G, Anderson N, et al., PROGRESS Collaborative Group. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke. 2009;40:2111–2115.
   PubMed Web of Science ®Google Scholar
• Pogue J, Walter SD, Yusuf S. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clin Trials. 2009;6:239–251.
   PubMed Web of Science ®Google Scholar
• Granger CB, Vogel V, Cummings SR, et al. Do we need to adjudicate major clinical events? Clin Trials. 2008;5:56–60.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Fiuzat M, Lindenfeld J, et al. Mode of death and hospitalization from the Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes. Am J Cardiol. 2011;108:1449–1457.
   PubMed Web of Science ®Google Scholar
• Näslund U, Grip L, Fischer-Hansen J, et al. The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee’s final decision on end-points. Eur Heart J. 1999;20:771–777.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Roe MT, Dyke CK, et al. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. Am Heart J. 2002;143:242–248.
   PubMed Web of Science ®Google Scholar
• Petersen JL, Haque G, Hellkamp AS, et al., MOST Clinical Events Committee. Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee. Contemp Clin Trials. 2006;27:260–268.
   PubMed Web of Science ®Google Scholar
• McGarvey LP, Magder S, Burkhart D, et al. Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations. Respir Med. 2012;106:515–521.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Harrington RA, Akkerhuis M, et al., For the PURSUIT Investigators. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med. 2001;2:187–194.
   PubMedGoogle Scholar
• Arnold DM, Lauzier F, Rabbat C, et al., PROTECT Investigators, on behalf of the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Adjudication of bleeding outcomes in an international thromboprophylaxis trial in critical illness. Thromb Res. 2013;131:204–209.
   PubMed Web of Science ®Google Scholar
• Smith SW, Diercks DB, Nagurney JT, et al. Central versus local adjudication of myocardial infarction in a cardiac biomarker trial. Am Heart J. 2013;165(273–279):e1.
   PubMedGoogle Scholar
• Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs – FDA and EMA assessment. N Engl J Med. 2014;370:794–797.
   PubMed Web of Science ®Google Scholar
• Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. Br Med J. 2014;348:g2366.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. Application number: 125469Orig1s000. Risk assessment and risk mitigation review(s). [cited 2015 Feb 3]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000RiskR.pdf.
   Google Scholar
• U.S. Food and Drugs Administration. Drug approval package. Trulicity (dulaglutide) injection. 2014. [cited 2015 Feb 4]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000TOC.cfm
   Google Scholar
• U.S. Food and Drugs Administration. FDA Briefing Document. NDA 206321. Liraglutide injection, 3mg. 2014. [cited 2015 Feb 4]. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm413317.pdf
   Google Scholar
• Blomgren KB, Sundström A, Steineck G, et al. Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diabetes Care. 2002;25:298–302.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drugs Administration. Drugs approval package. Byetta (Exenatide) Injection. [cited 2015 Feb 5]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_ByettaTOC.cfm
   Google Scholar
• U.S. Food and Drugs Administration. Drug Approval Package. Victoza (Liraglutide [rDNA]) Injection. 2010. [cited 2015 Feb 5]. Available from:http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000TOC.cfm
   Google Scholar
• U.S. Food and Drug Administration. Drug approval package. Tradjenta (linagliptin) tablets. 2011. [cited 2015 Feb 5]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000TOC.cfm
   Google Scholar
• U.S. Food and Drugs Administration. Drug Approval Package. Onglyza (saxagliptin) Tablets. [cited 2015 Feb 5]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000TOC.cfm
   Google Scholar
• U.S. Food and Drug Administration. Drug approval package. Januvia (Sitagliptin Phosphate) Tablets. [cited 2015 Feb 5]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000TOC.cfm
   Google Scholar
• U.S. Food and Drug Administration. Drug approval package. Nesina (alogliptin) tablets. 2014. [cited 2015 Feb 5]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000TOC.cfm
   Google Scholar
• U.S. Food and Drugs Administration. Drug approval package. Linagliptin and metformin tablets (2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg). 2013. [cited 2015 Feb 5]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201281_linagliptin_toc.cfm
   Google Scholar
• Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? Br Med J. 2013;346:f3680.
   PubMed Web of Science ®Google Scholar
• Yudkin JS, Richter B, Gale EA. Intensified glucose control in type 2 diabetes–whose agenda? Lancet. 2011;377:1220–1222.
   PubMed Web of Science ®Google Scholar
• Pogach L, Tseng CL, Soroka O, et al. A proposal for an out-of-range glycemic population health safety measure for older adults with diabetes. Diabetes Care. 2017;40:518–525.
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT, Einhorn D, Handelsman Y. Is HbA1c <7% a marker of poor performance in individuals >65 Years Old? Diabetes Care. 2017;40:526–528.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481–489.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Ambrosius WT, Brillon DJ, et al. Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010;33:983–990.
   PubMed Web of Science ®Google Scholar
• Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362:800–811.
   PubMed Web of Science ®Google Scholar
• Nichols GA, Joshua-Gotlib S, Parasuraman S. Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality. J Am Coll Cardiol. 2013;62:121–127.
   PubMed Web of Science ®Google Scholar
• Kontopantelis E, Springate DA, Reeves D, et al. Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study. Diabetologia. 2015;58:505–518.
   PubMed Web of Science ®Google Scholar
• Park C, Guallar E, Linton JA, et al. Fasting glucose level and the risk of incident atherosclerotic cardiovascular diseases. Diabetes Care. 2013;36:1988–1993.
   PubMed Web of Science ®Google Scholar
• Monami M, Vitale V, Lamanna C, et al. HbA1c levels and all-cause mortality in type 2 diabetic patients: epidemiological evidence of the need for personalised therapeutic targets. Nutr Metab Cardiovasc Dis. 2013;23:300–306.
   PubMed Web of Science ®Google Scholar
• Fagher K, Löndahl M. The impact of metabolic control and QTc prolongation on all-cause mortality in patients with type 2 diabetes and foot ulcers. Diabetologia. 2013;56:1140–1147.
   PubMed Web of Science ®Google Scholar
• Nicholas J, Charlton J, Dregan A, et al. Recent HbA1c values and mortality risk in type 2 diabetes. Population-based case-control study. PLoS One. 2013;8:e68008.
   PubMedGoogle Scholar
• Grembowski D, Ralston JD, Anderson ML. Hemoglobin A1c, comorbid conditions and all-cause mortality in older patients with diabetes: a retrospective 9-year cohort study. Diabetes Res Clin Pract. 2014;106:373–382.
   PubMed Web of Science ®Google Scholar
• Chiang HH, Tseng FY, Wang CY, et al. All-cause mortality in patients with type 2 diabetes in association with achieved hemoglobin A1c, Systolic blood pressure, and low-density lipoprotein cholesterol levels. PLoS One. 2014;9:e109501.
   PubMed Web of Science ®Google Scholar
• Li W, Katzmarzyk PT, Horswell R, et al. HbA1c and all-cause mortality risk among patients with type 2 diabetes. Int J Cardiol. 2016;202:490–496.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Holden SE, Jenkins‐Jones S, et al. Impact of differing glucose‐ lowering regimens on the pattern of association between glucose control and survival. Diabetes Obes Metab. 2018;20:821–830.
   Google Scholar
• Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22:1523–1534.
   PubMed Web of Science ®Google Scholar
• Stout RW. Diabetes and atherosclerosis–the role of insulin. Diabetologia. 1979;16:141–150.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Johnson J. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab. 2012;14:1–4.
   PubMed Web of Science ®Google Scholar
• Nolan CJ, Ruderman NB, Prentki M. Intensive insulin for type 2 diabetes: the risk of causing harm. Lancet Diabetes Endocrinol. 2013;1:9–10.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Holden SE. Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin. Diabetes Obes Metab. 2014;16:881–884.
   PubMed Web of Science ®Google Scholar
• Bittencourt MS, Hajjar LA. Insulin therapy in insulin resistance: could it be part of a lethal pathway? Atherosclerosis. 2015;240:400–401.
   PubMed Web of Science ®Google Scholar
• Schwartz SS, Jellinger PS, Herman ME. Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy’s safety profile. Postgrad Med. 2016;128:609–619.
   PubMed Web of Science ®Google Scholar
• Herman ME, O’Keefe JH, Bell DSH, et al. Insulin therapy increases cardiovascular risk: time for a sea of change in type 2 diabetes treatment. Prog Cardiovasc Dis. 2017. DOI:10.1016/j.pcad.2017.09.001
   PubMed Web of Science ®Google Scholar
• Krall LP, Entmacher PS, Drury TF. Joslin’s Diabetes Mellitus. 12th Edition. Philadelpia: Lea and Febiger; 1985. Chapter 45, Life cycle in diabetes: socioeconomic aspects; 907–936
   Google Scholar
• Gamble JM, Chibrikov E, Twells LK, et al. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Lancet Diabetes Endocrinol. 2017;5:43–52.
   PubMed Web of Science ®Google Scholar
• Damluji AA, Cohenc ER, Moscucci M, et al. Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease: insights from BARI-2D trial. Int J Cardiol. 2017;4.
   PubMedGoogle Scholar
• Nyström T, Bodegard J, Nathanson D, et al. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2017. DOI:10.1111/dom.12889
   Web of Science ®Google Scholar
• Mamza J, Mehta R, Donnelly R, et al. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study. Diab Vasc Dis Res. 2017;4:1–9.
   Web of Science ®Google Scholar
• Ballotari P, Vicentini M, Manicardi V, et al. Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy. BMC Cancer. 2017;17:703.
   PubMed Web of Science ®Google Scholar
• Morgan CL, Jenkins-Jones S, Evans M, et al. Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. Diabetes Obes Metab. 2012;14:424–432.
   PubMed Web of Science ®Google Scholar
• Zoungas S, Patel A, Chalmers J, et al. ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410–1418.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766–1777.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Jenkins-Jones S, et al. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012;35:299–304.
   PubMed Web of Science ®Google Scholar
• Vigneri R, Goldfine ID, Frittitta L. Insulin, insulin receptors, and cancer. J Endocrinol Invest. 2016;39:1365–1376.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Bosch J, Dagenais GR, et al., ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–328.
   PubMed Web of Science ®Google Scholar
• Supplementary appendix to the ORIGIN Trial. [cited 31 May 2021]. Available from: https://www.nejm.org/doi/suppl/10.1056/NEJMoa1203858/suppl_file/nejmoa1203858_appendix.pdf
   Google Scholar
• Pieber TR, Marso SP, McGuire DK, et al., DEVOTE Study Group. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2017 Sep 15. DOI:10.1007/s00125-017-4422-0.
   Web of Science ®Google Scholar
• Schernthaner G, Lehmann R, Prázný M, et al. Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). Cardiovasc Diabetol. 2017;16:137.
   PubMed Web of Science ®Google Scholar
• Arnold SV, Inzucchi SE, Tang F, et al. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR® Research to Practice project. Eur J Prev Cardiol. 2017;24:1637–1645.
   PubMed Web of Science ®Google Scholar
• Holden SE, Jenkins-Jones S, Currie CJ. Association between insulin monotherapy versus insulin plus metformin and the risk of all-cause mortality and other serious outcomes: a retrospective cohort study. PLoS One. 2016;11:e0153594.
   PubMed Web of Science ®Google Scholar